Fluoxetine induced dyskinesia.
Mander A, McCausland M, Workman B, Flamer H, Christophidis N.
Aust N Z J Psychiatry. 1994 Jun;28(2):328-30. doi: 10.1080/00048679409075647.
Co-catalpol alleviates fluoxetine-induced main toxicity: Involvement of ATF3/FSP1 signaling-mediated inhibition of ferroptosis.
Wu X, Guan Y, Wang J, Song L, Zhang Y, Wang Y, Li Y, Qin L, He Q, Zhang T, Long B, Ji L.
Phytomedicine. 2024 Apr;126:155340. doi: 10.1016/j.phymed.2024.155340. Epub 2024 Feb 5.
Fluoxetine overdose.
Finnegan KT, Gabiola JM.
Am J Psychiatry. 1988 Dec;145(12):1604. doi: 10.1176/ajp.145.12.1604b.
Fluoxetine-induced Stevens-Johnson syndrome and liver injury.
Agrawal R, Almoghrabi A, Attar BM, Gandhi S.
J Clin Pharm Ther. 2019 Feb;44(1):115-118. doi: 10.1111/jcpt.12760. Epub 2018 Oct 8.
Fluoxetine attenuates chlorpyrifos-induced neuronal injury through the PPARgamma, SIRT1, NF-kappaB, and JAK1/STAT3 signals.
Althagafy HS, Hassanein EHM.
Int Immunopharmacol. 2024 Jul 30;136:112335. doi: 10.1016/j.intimp.2024.112335. Epub 2024 May 29.
The safety of fluoxetine--an update.
Cooper GL.
Br J Psychiatry Suppl. 1988 Sep;(3):77-86.
Safety of antidepressants.
Swinkels JA, de Jonghe F.
Int Clin Psychopharmacol. 1995 Jan;9 Suppl 4:19-25. doi: 10.1097/00004850-199501004-00003.
Laryngeal dystonia.
Murray V.
Br J Psychiatry. 1995 Nov;167(5):698-9. doi: 10.1192/bjp.167.5.698b.
The side effect profile and safety of fluoxetine.
Wernicke JF.
J Clin Psychiatry. 1985 Mar;46(3 Pt 2):59-67.
The serotonin syndrome.
Sternbach H.
Am J Psychiatry. 1991 Jun;148(6):705-13. doi: 10.1176/ajp.148.6.705.
